Clinical Cancer Research Targets AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Yasui, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Yasui, W.
Clinical Cancer Research Vol. 7, 4067-4072, December 2001
© 2001 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Heparan Sulfate Enhances Invasion by Human Colon Carcinoma Cell Lines through Expression of CD44 Variant Exon 3

Hiroki Kuniyasu1, Naohide Oue, Masahiro Tsutsumi, Eiichi Tahara and Wataru Yasui

Department of Oncological Pathology, Cancer Center, Nara Medical University, Kashihara 634-8521, Japan [H. K., M. T.]; First Department of Pathology, Hiroshima University School of Medicine, Hiroshima, Japan [N. O., W. Y.]; and Hiroshima Cancer Seminar Foundation, Hiroshima 730-0052, Japan [E. T.]

CD44 variant exon (CD44v) 3 is a heparan sulfate-binding isoform of CD44. The role of CD44v3 in invasion and metastasis associated with heparan sulfate in colon cancer cell lines and cases of colon cancer was examined. Expression of CD44v3 mRNA and protein was observed in five of six human colorectal cancer cell lines. Colo320 and WiDr cells expressed CD44v3 at high levels. Heparan sulfate treatment increased the invasive activity of Colo320 and WiDr cells to rates 14.3 and 12.6 times higher, respectively, than that of untreated cells. However, heparan sulfate treatment did not affect cell growth. Repression of CD44v3 protein production by antisense S-oligodeoxynucleotide treatment reduced the binding affinities and capacities for heparan sulfate by Colo320 and WiDr cells in comparison with that of control cells, and it also reduced the invasiveness of both cell lines to one-fifth that of control cells. In heparan sulfate-treated Colo320 cells, the levels of CD44v3 protein in the Triton X-100-insoluble fraction and moesin-precipitated fraction were increased, suggesting that heparan sulfate treatment facilitates association of CD44 molecules with the cytoskeleton. Immunohistochemical analysis showed CD44v3 to be expressed in 21 of 37 (57%) colorectal cancer cases. Positive CD44v3 expression was associated with more advanced pathological stage and poorer prognosis than negative CD44v3 expression. These data support a role for CD44v3 in invasion and metastasis by colorectal carcinoma cells.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
H. Kuniyasu, H. Ohmori, T. Sasaki, T. Sasahira, K. Yoshida, Y. Kitadai, and I. J. Fidler
Production of Interleukin 15 by Human Colon Cancer Cells Is Associated with Induction of Mucosal Hyperplasia, Angiogenesis, and Metastasis
Clin. Cancer Res., October 15, 2003; 9(13): 4802 - 4810.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Ikeguchi, K. Fukuda, K.-i. Yamaguchi, A. Kondo, S.-i. Tsujitani, and N. Kaibara
Quantitative Analysis of Heparanase Gene Expression in Esophageal Squamous Cell Carcinoma
Ann. Surg. Oncol., April 1, 2003; 10(3): 297 - 304.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.